{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:31:17Z","timestamp":1791657077716,"version":"4.3.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human immunodeficiency virus (HIV-1)\u2013associated tuberculous meningitis (TBM) is the most lethal form of extrapulmonary tuberculosis, with a high mortality rate in sub-Saharan Africa. Due to the limited diagnostic performance of current testing, empiric treatment is frequently required as untreated TBM is almost universally fatal. Xpert MTB\/RIF Ultra (Xpert Ultra) is the World Health Organization recommended first-line diagnostic test for TBM but is costly relative to the standard of care (SOC). We performed a cost-effectiveness analysis of Xpert Ultra for HIV-associated TBM in Zambia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a decision-analytic model comparing a diagnostic strategy guided by CSF Xpert Ultra plus the SOC (cerebrospinal fluid biochemistry and clinical suspicion) versus the SOC alone in adults with HIV and suspected TBM. Costs were calculated from a healthcare perspective, including medication, supplies, personnel, and overhead. The primary outcome was the incremental cost-effectiveness ratio in US dollars per quality-adjusted life-year gained. Sensitivity analyses and cost-effectiveness acceptability curves assessed robustness across a range of willingness-to-pay thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Xpert Ultra plus the SOC was cost-effective, yielding an incremental cost-effectiveness ratio of $242.76 per quality-adjusted life-year gained. The number needed to test to prevent 1 TBM death was 125. Sensitivity analyses showed that cost-effectiveness was most influenced by TBM prevalence, the TBM mortality rate in treated patients, and the probability of empiric treatment. Xpert Ultra was approximately 88% likely to be cost-effective across a broad willingness-to-pay range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Xpert Ultra is cost-effective for diagnosing HIV-associated TBM in Zambia. These findings support World Health Organization guidelines recommending Xpert Ultra in high-burden, resource-limited settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag348","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:35:39Z","timestamp":1781004939000},"page":"260-266","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness Analysis of Xpert MTB\/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-563X","authenticated-orcid":false,"given":"Omar K","family":"Siddiqi","sequence":"first","affiliation":[{"name":"Global Neurology Program, Department of Neurology, Beth Israel Deaconess Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Center for Vaccines and Virology Research, Department of Internal Medicine, Beth Israel Deaconess Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Internal Medicine, University of Zambia School of Medicine , Lusaka ,","place":["Zambia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Jahn","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL\u2014University for Health Sciences and Technology , Hall in Tirol ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Rochau","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL\u2014University for Health Sciences and Technology , Hall in Tirol ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5361-4076","authenticated-orcid":false,"given":"Stewart","family":"Walukaga","sequence":"additional","affiliation":[{"name":"RAND Graduate School, RAND , Santa Monica, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-0231","authenticated-orcid":false,"given":"Radha","family":"Rajasingham","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical Center Division of Infectious Diseases and International Medicine, Department of Medicine, , Minneapolis, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-7671","authenticated-orcid":false,"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL\u2014University for Health Sciences and Technology , Hall in Tirol ,","place":["Austria"]},{"name":"Center for Health Decision Science, Departments of Epidemiology and Health Policy & Management, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]},{"name":"Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026090211570512200_ciag348-B1","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00652-19","article-title":"Prospective cohort study on performance of cerebrospinal fluid (CSF) Xpert MTB\/RIF, CSF lipoarabinomannan (LAM) lateral flow assay (LFA), and urine LAM LFA for diagnosis of tuberculous meningitis in Zambia","volume":"57","author":"Siddiqi","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2026090211570512200_ciag348-B2","doi-asserted-by":"crossref","first-page":"19184","DOI":"10.7448\/IAS.17.1.19184","article-title":"Meningitis in HIV-positive patients in sub-Saharan Africa: a review","volume":"17","author":"Veltman","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2026090211570512200_ciag348-B3","doi-asserted-by":"crossref","first-page":"ofaa257","DOI":"10.1093\/ofid\/ofaa257","article-title":"Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis","volume":"7","author":"Stadelman","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026090211570512200_ciag348-B4","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1186\/s12913-024-11914-z","article-title":"Health technology assessment to support health benefits package design: a systematic review of economic evaluation evidence in Zambia","volume":"24","author":"Simangolwa","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2026090211570512200_ciag348-B5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"key":"2026090211570512200_ciag348-B6","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/cid\/ciu191","article-title":"Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults","volume":"58","author":"Siddiqi","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026090211570512200_ciag348-B7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1473-3099(10)70138-9","article-title":"Tuberculous meningitis: a uniform case definition for use in clinical research","volume":"10","author":"Marais","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2026090211570512200_ciag348-B8","volume-title":"Amua: an open source modeling framework","author":"Ward","year":"2024","edition":"0.3.0 ed"},{"key":"2026090211570512200_ciag348-B9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"32","author":"Caro","year":"2012","journal-title":"Med Decis Making"},{"key":"2026090211570512200_ciag348-B10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2","volume":"32","author":"Roberts","year":"2012","journal-title":"Med Decis Making"},{"key":"2026090211570512200_ciag348-B11","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1016\/S2352-3018(22)00198-9","article-title":"Differences in healthy longevity by HIV status and viral load among older South African adults: an observational cohort modelling study","volume":"9","author":"Payne","year":"2022","journal-title":"Lancet HIV"},{"key":"2026090211570512200_ciag348-B12","author":"World Health Organization"},{"key":"2026090211570512200_ciag348-B13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1473-3099(19)30550-X","article-title":"Xpert MTB\/RIF ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study","volume":"20","author":"Cresswell","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026090211570512200_ciag348-B14","doi-asserted-by":"crossref","first-page":"21823","DOI":"10.1038\/s41598-020-78737-w","article-title":"Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV","volume":"10","author":"Steffen","year":"2020","journal-title":"Sci Rep"},{"key":"2026090211570512200_ciag348-B15","doi-asserted-by":"crossref","first-page":"e1133","DOI":"10.1016\/S2214-109X(17)30367-4","article-title":"Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial","volume":"5","author":"Thomas","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2026090211570512200_ciag348-B16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.5588\/ijtld.15.0253","article-title":"Improved diagnostic sensitivity for tuberculous meningitis with Xpert\u00ae MTB\/RIF of centrifuged CSF","volume":"19","author":"Bahr","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026090211570512200_ciag348-B17","first-page":"21","article-title":"Adverse events to first line anti-tuberculosis drugs in patients co-infected with HIV and tuberculosis","volume":"14","author":"Michael","year":"2016","journal-title":"Ann Ib Postgrad Med"},{"key":"2026090211570512200_ciag348-B18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"2026090211570512200_ciag348-B19","author":"World Health Organization"},{"key":"2026090211570512200_ciag348-B20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7326\/0003-4819-129-10-199811150-00005","article-title":"Short-course prophylaxis against tuberculosis in HIV-infected persons: a decision and cost-effectiveness analysis","volume":"129","author":"Rose","year":"1998","journal-title":"Ann Intern Med"},{"key":"2026090211570512200_ciag348-B21","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(19)30164-0","article-title":"Point of care Xpert MTB\/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation","volume":"7","author":"Pooran","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2026090211570512200_ciag348-B22","author":"World Bank"},{"key":"2026090211570512200_ciag348-B23","author":"Oanda Corporation"},{"key":"2026090211570512200_ciag348-B24","author":"Institute for Clinical Effectiveness and Health Policy (IECS)"},{"key":"2026090211570512200_ciag348-B25","volume-title":"Macroeconomics and health: investing in health for economic development","author":"WHO Commission on Macroeconomics and Health","year":"2001"},{"key":"2026090211570512200_ciag348-B26","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Health"},{"key":"2026090211570512200_ciag348-B27","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures","volume":"11","author":"Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2026090211570512200_ciag348-B28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Making"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag348\/68500340\/ciag348.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/260\/68500340\/ciag348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/2\/260\/68500340\/ciag348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:57:36Z","timestamp":1788364656000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/2\/260\/8704665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,9]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag348","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,15]]},"published":{"date-parts":[[2026,6,9]]}}}